| Adverse event | Subgroup analysis | |||
| LNZ ≤600 mg | LNZ >600 mg | p-value | ||
| Total adverse events presumably due to linezolid | 22/34 (64.7) | 14/20 (70.0) | 8/14 (57.1) | 0.49 |
| Major adverse events | 21/28 (75.0) | 16/20 (80.0) | 5/8 (62.5) | 0.37 |
| Anaemia | 9/29 (31.0) | 5/21 (23.8) | 4/8 (50.0) | 0.21 |
| Leukopenia | 4/29 (13.8) | 1/21 (4.8) | 3/8 (37.5) | 0.05 |
| Thrombocytopenia | 5/29 (17.2) | 2/21 (9.5) | 3/8 (37.5) | 0.11 |
| Peripheral neuropathy | 16/29 (55.2) | 11/21 (52.4) | 5/8 (62.5) | 0.70 |
| Optic neuritis | 5/25 (20.0) | 2/17 (11.8) | 3/8 (37.5) | 0.28 |
| Gastro-intestinal disorders | 5/28 (17.9) | 2/21 (9.5) | 3/7 (42.9) | 0.08 |
| Exposure to linezolid days | 315 (178–540) | 270 (93–720) | 330 (270–490) | 0.64 |
Data are presented as n/n (%) or median (interquartile range), unless otherwise stated. LNZ: linezolid daily dose.